Research Paper Volume 12, Issue 1 pp 571—592

STARD1 and NPC1 expression as pathological markers associated with astrogliosis in post-mortem brains from patients with Alzheimer's disease and Down syndrome

Figure 2. Hippocampal expression of AD biomarkers and lysosomal/mitochondrial cholesterol carriers. (A) Representative images of immunohistochemistry of paraffin sections (5 μm) against Aβ42, p-tau, StARD1 and NPC1 for CA1, CA2 and CA3 hippocampal regions from AD (n=7), DS (n=7), and control (n=7) subjects. Positive immunoreactivity is shown by black arrows. Scale bar: 100 μm. (B) Quantitation of IHC shown in A using Image J software as described in Supplementary methods. For each hippocampal region, the % of immunolabeled area was normalized to control group. (*) p<0.05; (**) p<0.01; (***) p<0.001. (C) Spearman’s correlation values between IHC-immunolabeling for Aβ42 and StARD1 in each hippocampal region.